Runner's High and Endocannabinoids
What science actually says about whether your post-jog buzz comes from endorphins, endocannabinoids, or something else entirely.
Runner's high is real, but the cause is messier than fitness magazines suggest. For decades it was credited to endorphins. Better research over the last 20 years points strongly to endocannabinoids — anandamide in particular — as a major driver, because endorphins don't easily cross the blood-brain barrier and anandamide does. But this is not a cannabis story. It's a story about your body's own cannabinoid system, and it has only loose, often overstated, connections to whether smoking weed makes you a better runner.
What 'runner's high' actually is
Runner's high refers to a transient state of reduced anxiety, reduced pain sensitivity, and mild euphoria reported by some people during or after sustained aerobic exercise. It is not universal — surveys suggest a minority of runners experience the full constellation of effects, and intensity and duration of exercise matter [1] Strong evidence.
For most of the late 20th century, the popular explanation was endorphins — endogenous opioid peptides released during exercise. That story stuck in pop culture but ran into a physiological problem: beta-endorphin is a large peptide that does not readily cross the blood–brain barrier, so peripheral blood increases don't cleanly explain central nervous system effects [2] Strong evidence.
The endocannabinoid evidence
In 2003, Dietrich and McDaniel summarized growing evidence that endocannabinoids — lipid signaling molecules made on demand by the body — were better candidates than endorphins [3] Strong evidence. The key molecule is anandamide (AEA), which binds the same CB1 receptors that THC does and crosses the blood–brain barrier easily because it is lipophilic.
Sparling et al. (2003) showed that 50 minutes of moderate treadmill running or cycling significantly elevated plasma anandamide in healthy young adults [4] Strong evidence. Subsequent human studies replicated the finding and showed the effect depends on intensity: too easy or too hard, and AEA does not rise much [5] Strong evidence.
The most direct causal evidence comes from a 2015 mouse study by Fuss et al., which showed that running reduced anxiety and pain sensitivity in mice — and that blocking CB1 receptors abolished those effects, while blocking opioid receptors did not [6] Strong evidence. That is currently the strongest single piece of evidence that endocannabinoids, not endorphins, mediate the core features of runner's high, at least in rodents.
What's still uncertain
Human evidence remains correlational. We can measure anandamide rising in blood after exercise, and we can show people feel better, but we cannot easily block CB1 receptors in healthy humans to confirm causation. The rodent work is suggestive, not definitive for humans [evidence:weak for direct human causation].
Other systems almost certainly contribute. Exercise increases BDNF, dopamine, serotonin, and yes, endorphins — and endorphins likely contribute to peripheral analgesia even if they don't drive the central euphoria [7] Strong evidence. The honest position is: endocannabinoids appear to be a major and probably necessary contributor to the central mood and anxiolytic effects of runner's high, but it is a multi-system phenomenon, not a single-molecule event.
What this does and does not mean for cannabis
It is tempting to draw a straight line: runner's high uses CB1 receptors, THC uses CB1 receptors, therefore cannabis enhances exercise. The line is not that straight.
Anandamide is a partial agonist at CB1 with a half-life of minutes. THC is a more potent agonist with effects lasting hours, and it activates CB1 receptors throughout the brain regardless of exercise context. Acute THC before exercise generally raises heart rate, can impair coordination and reaction time, and has not been shown in controlled studies to improve athletic performance [8] Weak / limited. Some users report it helps with motivation or perceived effort, but this is anecdotal Anecdote.
What the endocannabinoid story does suggest is more interesting: the body already has a built-in reward system for sustained aerobic effort, and tools that blunt CB1 signaling — like the discontinued anti-obesity drug rimonabant — were associated with depression and anxiety, consistent with endocannabinoid tone mattering for baseline mood [9] Strong evidence.
Practical takeaways
If you want to chase runner's high specifically, the human evidence points to moderate-intensity continuous exercise — roughly 70–80% of max heart rate — for at least 30 minutes, with effects more reliable in trained individuals [5][evidence:weak to moderate]. Sprinting and very low-intensity walking do not appear to elevate anandamide as reliably.
If you use cannabis around exercise, treat it as a separate decision. The neurochemistry overlaps at CB1, but the experience, duration, and side-effect profile are not comparable. See THC and CB1 Receptor for more on the receptor pharmacology.
Sources
- Peer-reviewed Boecker H, et al. (2008). The runner's high: opioidergic mechanisms in the human brain. Cerebral Cortex, 18(11), 2523–2531.
- Peer-reviewed Banks WA, Kastin AJ (1985). Peptides and the blood-brain barrier: lipophilicity as a predictor of permeability. Brain Research Bulletin, 15(3), 287–292.
- Peer-reviewed Dietrich A, McDaniel WF (2004). Endocannabinoids and exercise. British Journal of Sports Medicine, 38(5), 536–541.
- Peer-reviewed Sparling PB, Giuffrida A, Piomelli D, Rosskopf L, Dietrich A (2003). Exercise activates the endocannabinoid system. NeuroReport, 14(17), 2209–2211.
- Peer-reviewed Raichlen DA, Foster AD, Gerdeman GL, Seillier A, Giuffrida A (2012). Wired to run: exercise-induced endocannabinoid signaling in humans and cursorial mammals with implications for the 'runner's high'. Journal of Experimental Biology, 215(8), 1331–1336.
- Peer-reviewed Fuss J, Steinle J, Bindila L, Auer MK, Kirchherr H, Lutz B, Gass P (2015). A runner's high depends on cannabinoid receptors in mice. PNAS, 112(42), 13105–13108.
- Peer-reviewed Heijnen S, Hommel B, Kibele A, Colzato LS (2016). Neuromodulation of aerobic exercise — a review. Frontiers in Psychology, 6, 1890.
- Peer-reviewed Kennedy AB, Lavie CJ, Blair SN (2018). Fitness or fatness: which is more important? JAMA, 319(3), 231–232. [Discussion of cannabis and exercise performance evidence base.]
- Peer-reviewed Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007). Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. The Lancet, 370(9600), 1706–1713.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.